Physician profile
Nathan Porter
NPI 1922880251
$2,148.51
in general payments reported to CMS, 2019-2025
18 companies · $781 in 2025
The $781 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $44.57 · 2024: $1,323 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $528.79 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $372.89 | 2024-2025 | Caplyta |
| Lundbeck LLC | $253.68 | 2024-2025 | Rexulti |
| Corium, LLC | $207.20 | 2023-2025 | Azstarys |
| Tris Pharma INC | $204.90 | 2024-2025 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $192.57 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $76.56 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $54.67 | 2024-2025 | Fanapt, Hetlioz |
| Neos Therapeutics, Lp | $46.90 | 2024-2025 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $39.33 | 2024-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $32.02 | 2025 | Cobenfy |
| Alkermes, INC. | $31.05 | 2024 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $24.83 | 2025 | Qelbree |
| Axsome Therapeutics, INC. | $20.13 | 2024 | Auvelity |
| Noven Therapeutics, LLC | $19.25 | 2024 | Xelstrym |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $15.51 | 2025 | Relexxii |
| Collegium Pharmaceutical, INC. | $14.71 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $13.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.